Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Peter Wassmer"'
Autor:
Ravi Korabathina, Jamie Porcadas, Kevin E. Kip, Puja R. Korabathina, Andrew D. Rosenthal, Peter Wassmer
Publikováno v:
Tex Heart Inst J
Recurrent takotsubo cardiomyopathy (TTC) and the clinical profiles and outcomes of patients have not been fully evaluated, nor has the effect of left ventricular ballooning pattern. After searching the medical literature for reports of patients with
Autor:
Peter Wassmer, Samuel R. Money, Shabbir A. Dharamsey, Christopher J. White, Stephen Jenkins, Stephen R. Ramee, Reynaldo Mulingtapang, Sylvia Griffin
Publikováno v:
Journal of the American College of Cardiology. 25:381A-382A
Central vein occlusion is a common cause of morbidity in patients with upper extremity hemodialysis (HD) access sites and a history of ipsilateral indwelling central lines. We analyzed the results of two percutaneous treatments, balloon angioplasty (
Autor:
Jill Lindberg, Stephen R. Ramee, Reynaldo Mulingtapang, Julio Figueroa, Sylvia Griffin, Tyrone J. Collins, Christopher J. White, Stephen Jenkins, Peter Wassmer
Publikováno v:
Journal of the American College of Cardiology. 25:263A
Hemodialysis access thrombosis is the leading cause of hospitalization in the dialysis population. Thrombosis of polytetrafluoroethylene (PTFE) grafts can be treated either with surgical thrombectomy or percutaneous thrombolysis. Percutaneous aspirat
Publikováno v:
Cellular Immunology. 94:299-311
This report describes a new rat monoclonal IgM/k antibody, monoclonal antibody (MAb) 2B6, which reacts with a cell surface antigen present on a subpopulation of both thymocytes (85%) and peripheral T lymphocytes (55–60%). The antigen recognized by
Autor:
Wolfgang Müller, Otto Madic, Peter Wassmer, Christian Herzog, Hannes Stockinger, C. Walker, Werner J. Pichler, Christian Reiter, G. Riethmüller, Peter Rieber
Publikováno v:
Journal of Autoimmunity. 2:627-642
Eight patients with arthritis (seven with rheumatoid, one with psoriatic arthritis) were treated for 7 d with a daily injection of 10 mg of mouse monoclonal anti-CD4 antibodies (three with VIT4, five with MT151). With the exception of a short-lasting